A prospective, observational study assessing impact of pharmaceutical care programs for the management of contraindicated drug-drug interactions (DDIs) in direct-acting antivirals (DAAs) therapy
Latest Information Update: 05 Jan 2022
At a glance
- Drugs Asunaprevir/daclatasvir (Primary) ; Elbasvir/grazoprevir (Primary) ; Glecaprevir/pibrentasvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 05 Jan 2022 New trial record
- 01 Jan 2022 Results published in the Journal of the Formosan Medical Association